Mizuno S, Bogaard HJ, Kraskauskas D, Alhussaini A, Gomez-Arroyo J, Voelkel NF, Ishizaki T. p53 Gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice. Am J Physiol Lung Cell Mol Physiol 300: L753-L761, 2011. First published February 18, 2011 doi:10.1152/ajplung.00286.2010.-Chronic hypoxia induces pulmonary arterial remodeling, resulting in pulmonary hypertension and right ventricular hypertrophy. Hypoxia has been implicated as a physiological stimulus for p53 induction and hypoxia-inducible factor-1␣ (HIF-1␣). However, the subcellular interactions between hypoxic exposure and expression of p53 and HIF-1␣ remain unclear. To examine the role of p53 and HIF-1␣ expression on hypoxia-induced pulmonary arterial remodeling, wild-type (WT) and p53 knockout (p53KO) mice were exposed to either normoxia or hypoxia for 8 wk. Following chronic hypoxia, both genotypes demonstrated elevated right ventricular pressures, right ventricular hypertrophy as measured by the ratio of the right ventricle to the left ventricle plus septum weights, and vascular remodeling. However, the right ventricular systolic pressures, the ratio of the right ventricle to the left ventricle plus septum weights, and the medial wall thickness of small vessels were significantly greater in the p53KO mice than in the WT mice. The p53KO mice had lower levels of p21 and miR34a expression, and higher levels of HIF-1␣, VEGF, and PDGF expression than WT mice following chronic hypoxic exposure. This was associated with a higher proliferating cell nuclear antigen expression of pulmonary artery in p53KO mice. We conclude that p53 plays a critical role in the mitigation of hypoxia-induced small pulmonary arterial remodeling. By interacting with p21 and HIF-1␣, p53 may suppress hypoxic pulmonary arterial remodeling and pulmonary arterial smooth muscle cell proliferation under hypoxia. p21; hypoxia-inducible factor-1␣, vascular endothelial growth factor; platelet-derived growth factor PULMONARY HYPERTENSION COMMONLY occurs in highland residents and in patients with pulmonary disorders associated with chronic hypoxia, most notably patients with chronic obstructive pulmonary disease, and may ultimately lead to right heart failure and death (4, 23, 27, 34, 35, 41) . Prolonged hypoxic exposure is associated with cellular and histological changes in the pulmonary vascular wall. The major characteristic pathological findings of pulmonary vascular remodeling are increased wall thickening of pulmonary vessels and muscularization of small arteries. In animals, hypoxia has been shown to cause pulmonary vascular wall thickening by inducing pulmonary arterial smooth muscle cell (PASMC) proliferation (44, 46) . Several in vitro studies have shown that hypoxia stimulates proliferation of pulmonary vascular cells (9, 14, 24, 26, 40) .
PULMONARY HYPERTENSION COMMONLY occurs in highland residents and in patients with pulmonary disorders associated with chronic hypoxia, most notably patients with chronic obstructive pulmonary disease, and may ultimately lead to right heart failure and death (4, 23, 27, 34, 35, 41) . Prolonged hypoxic exposure is associated with cellular and histological changes in the pulmonary vascular wall. The major characteristic pathological findings of pulmonary vascular remodeling are increased wall thickening of pulmonary vessels and muscularization of small arteries. In animals, hypoxia has been shown to cause pulmonary vascular wall thickening by inducing pulmonary arterial smooth muscle cell (PASMC) proliferation (44, 46) . Several in vitro studies have shown that hypoxia stimulates proliferation of pulmonary vascular cells (9, 14, 24, 26, 40) .
Under normal physiological conditions, the majority of pulmonary vascular cells are in a quiescent state, and proliferation of PASMCs requires the cells to enter the cell cycle. The most important molecular event necessary for the progress of the cell cycle is phosphorylation of the retinoblastoma protein by cyclin-dependent kinase (CDK)-cyclin complexes. CDK activity can be inhibited by CDK inhibitors, which arrest the cell cycle at each corresponding phase and inhibit cell proliferation (18) . The endogenous CDK inhibitor p21 plays a critical role in PASMC proliferation via induction of the tumor suppressor p53 (29, 31) and has been identified as a key regulator of the cell cycle in cells exposed to hypoxia and oxidative stress (1, 28, 38) . In tumors expressing wild-type (WT) p53, hypoxic cells undergo apoptosis strongly correlated with the hypoxic regions, whereas tumors expressing mutant p53 exhibit lower levels of apoptosis in hypoxic regions (17) . p53Ϫ/Ϫ mouse embryo fibroblasts are more resistant to hypoxia-induced apoptosis and have selective growth advantages compared with WT p53 cells (45) . These results support the view that the p53 protein opposes cell proliferation under hypoxia. Hypoxic p53 accumulation has been linked to the hypoxia-inducible factor-1␣ (HIF-1␣), which is known as a central transcriptional factor operating during hypoxia toward angiogenesis (2, 5) . In addition, recently, microRNAs (miRNAs), which are regulated by p53, have been identified by several groups (6, 20) . The miR34a has been shown to be the most significant miRNA induced by p53, which, in turn, is closely related to induction of apoptosis and cell cycle arrest in cancer cells (8, 10, 36, 42) .
Based on these findings, we assumed that, under hypoxic conditions, HIF-1␣ and p53 are key mediators in hypoxic pulmonary arterial remodeling and hypoxic PASMC proliferation. However, little is known regarding the interaction of p53 and HIF-1␣ in pulmonary arteries exposed to hypoxia. The purpose of this study was to clarify the participation and regulation of the cell cycle molecules by p53 during hypoxia. We show, for the first time, that hypoxic pulmonary vascular remodeling is augmented in p53 knockout (p53KO) mice and that these effects may be associated with an increase of HIF-1␣ and loss of p21 expression in lung vessels.
MATERIAL AND METHODS
Chemicals. Chemicals and materials were obtained from the following sources: the ECL system from Amersham (Buckinghamshire, UK); Moloney murine leukemia virus reverse transcriptase from Toyobo (Osaka, Japan); a Quantitech SYBAR Green polymerase chain reaction (PCR) kit, RNeasy Midi kit, and RNeasy Micro kit from Qiagen (Santa Clarita, CA); 4 -12% Bis-Tris Nupage gels and MES-SDS running buffer from Invitrogen (Carlsbad, CA); a DC protein assay kit and polyvinylidene difluoride membranes from Bio-Rad Laboratories (Richmond, CA); and rabbit anti-p21 polyclonal antibody, rabbit anti-p53 polyclonal antibody, mouse anti-p53 monoclonal antibody, mouse monoclonal anti-HIF-1␣ antibody, rabbit polyclonal anti-proliferating cell nuclear antigen (PCNA) antibody, mouse anti-Lamin A/C monoclonal antibody, mouse anti-␤-actin monoclonal antibody, and horseradish peroxidase-conjugated goat anti-mouse and goat anti-rabbit from Santa Cruz Biotechnology. All other chemicals were purchased from Sigma (St. Louis, MO).
Animals. Trp53 tm1tyj /J (p53KO) and WT 6-wk-old male mice were obtained from Jackson Laboratory (Sacramento, CA), and the genotypes were confirmed by PCR of genomic DNA. WT and p53KO mice were placed in a normobaric hypoxic-air chamber (22) or exposed to normoxia in the same chamber for 8 wk. Oxygen concentration was maintained at 10% by controlling the flow rates of compressed nitrogen and air. The oxygen concentration of the cage was monitored continuously. The mice were weighed every 2 wk, and blood was obtained by cardiac puncture for hematocrit after the 8-wk hypoxic exposure. After hemodynamic measurement, the heart, lungs, and trachea were removed. Right ventricular (RV) hypertrophy was measured as a ratio of RV weight to left ventricular plus septal weight (RV/LVϩS). One-half of the lungs were snap frozen for subsequent protein analysis, or immediately submerged in RNAlater solution for RNA analysis, and the other one-half was fixed by intratracheal infusion of 4% phosphate-buffered formalin at a pressure of 23 cmH 2O and used for histological examination, or inflated with 50% vol/vol mixture of Tissue-Tek OCT compound (Sakura Finetek, Torrance, CA) in 10% RNase-free sucrose, stored at Ϫ80°C, and used for laser microdissection (LMD) of small pulmonary arteries. All procedures were performed in accordance with the National Institutes of Health Guidelines for the Care and Use of Animals and conformed with the Guidelines for Animal Experiments of the University of Fukui and Virginia Commonwealth University.
Echocardiography. Doppler echocardiography was performed using the Vevo770 imaging system (VisualSonics, Toronto, Canada) directly after the hypoxic exposure. Superficial anesthesia with ketamine-xylazine was used to obtain two-dimensional, M-mode, and Doppler imaging in both long-axis (four-chamber) and short-axis views, using a 30-MHz probe. Measurements were made of the RV inner diameter in diastole (long axis).
Hemodynamic measurements. Eight weeks after hypoxic exposure, hemodynamic measurements were made using a 4.5-mm conductance catheter (Millar Instruments, Houston, TX) and the Powerlab data acquisition system (AD Instruments, Colorado Springs, CO). The mice were anesthetized with isoflurane, intubated and placed in a supine position, and ventilated with either normoxic or hypoxic air (10% oxygen concentration). After a median sternotomy, the RV outflow tract was punctured with a 23G needle, and the catheter was introduced in the RV cavity through the incision, and placement was verified via the pressure waveform. The RV pressure and pressurevolume loop of the RV (Supplemental Fig. 1 ; the online version of this article contains supplemental data) was continuously monitored using Chart 5 pro software (AD Instrument, Colorado Springs, CO).
Histological evaluation. The lungs were fixed by intratracheal infusion of 4% phosphate-buffered formalin at a pressure of 23 cmH2O. The tissues were embedded in paraffin, sectioned at a thickness of 2 m for light microscopy, and stained with hematoxylineosin and elastica-van Gieson. Pulmonary vascular remodeling was assessed by measuring media thickness of vessels (diameter 50 -150 m) indexed to terminal bronchioles. The percent wall thickness was measured using an ocular micrometer by an observer who was blinded to both the genotypes and treatments of the mice. Percent wall thickness was expressed as the medial wall thickness (the distance between the internal and external lamina) divided by the diameter of the vessel (the distance between the external lamina) ϫ 100. For each mouse, Ͼ20 arteries were analyzed in multiple lung sections.
Immunohistochemical staining of small vessels. The slides with 5-m paraffin sections were deparaffinized in xylene, rehydrated, and then submitted to microwave treatment in 10 mM citric acid monohydrate solution. After quenching of endogenous peroxidase with 3% H 2O2 for 15 min, the slides were incubated overnight with anti-PCNA rabbit polyclonal antibody (1:100 dilution), anti-HIF-1␣ mouse monoclonal antibody (1:50 dilution), anti-p53 mouse monoclonal antibody (1:100 dilution), or anti-p21 rabbit polyclonal antibody (1:100 dilution) at 4°C and were subsequently incubated with biotinylated anti-rabbit or mouse IgG antibody for 30 min at room temperature. Following this secondary antibody application, sections were incubated with ABC complex (Vector, Burlingame, CA) for 30 min at room temperature and developed with diaminobenzidine (Vector, Burlingame, CA) until the desired stain intensity had developed. Washing with water stopped the diaminobenzidine reaction. A light hematoxylin counterstain was applied. Sections were dehydrated by sequential immersion in 70% ethanol, 95% ethanol, 100% ethanol, and then xylene before a coverslip was placed on the section. For counting of the number of proliferating vascular cells, 10 random pulmonary arteries per tissue section stained with anti-PCNA antibody were captured at a ϫ400 magnification, and then the number of PCNA-positive cells in the medial wall of pulmonary vessels was counted. The length of the basal membrane of the pulmonary arteries was measured by manual tracing using AxioVision Imaging System software and used as the reference for the number of PCNA-positive cells.
Real-time reverse transcription-PCR analysis of mRNA and miRNA using LightCycler480. Isolation of total RNA from lung tissue was performed using an miRNeasy Midi kit (Qiagen), according to the manufacturer's protocol. Total RNA (1 g) was reverse-transcribed using random primer and MultiScribe reverse transcription (RT) (High-Capacity cDNA Archive kit, Applied Biosystems, Foster City, CA) for mRNA analysis and miScript RT kit (Qiagen) for miRNA analysis. PCR was performed with the resulting RT products using specific oligonucleotide primers for each target genes. The sequence of the forward primer for p21 was 5=-TCCAGACATTCAGAGC-CACA-3=, and the reverse primer was 5=-CGAAGAGACAACG-GCACACT-3=. The sequence of the forward primer for p53 was 5=-ATTTGTATCCCGAGTATCTG-3=, and that of the reverse primer was 5=-GGTATACTCAGAGCCGGCCT-3=. The sequence of the forward primer for VEGF was 5=-ACTGGACCCTGGCTTTACTG-3=, and that of the reverse primer was 5=-TCACTTCATGGGACTTCTGC-3=. The sequence of the forward primer for PDGF-A was 5=-TAACACCAG-CAGCGTCAAGT-3=, and that of the reverse primer was 5=-CCTCACCTGGACCTCTTTCA-3=. The sequence of the forward primer for PDGF-B was 5=-CTCTGCTGCTACCTGCGTCT-3=, and that of the reverse primer was 5=-CAGCCCCATCTTCATCTACG-3=. The sequence of the forward primer for PDGF-C was 5=-CCAGCGA-CAAGGAACAGAAC-3=, and that of the reverse primer was 5=-TAATCTCCACACCAGCACCA-3=. The sequence of the forward primer for PDGF-D was 5=-CAGTCTTCTTCCCACGATGC-3=, and that of the reverse primer was 5=-ATGTCCAGGCTCAAACTTCA-3=. The sequence of the forward primer for glucose transporter 1 (GLUT-1) was 5=-GCTTCCTGCTCATCAATCGT-3=, and that of the reverse primer was 5=-CTTCTTCTCCCGCATCATCT-3=. The sequence of the forward primer for ␤-actin was 5=-CCGTGAAAAGATGACCCAGA-3=, and that of the reverse primer 5=-AGAGGCATACAGGGACAGCA-3=. The sequence of the primer for miR34a was 5=-GGCAGTGTCT-TAGCTGGTTGT-3=, and the sequence of the primer for miR103 was 5=-CAGCATTGTACAGGGCTATGA-3=. All PCR reactions were performed with a LightCycler480 PCR system (Roche Diagnostics, Meylan, France) using DNA binding SYBR Green dye for the detection of PCR products. The cycling conditions were as follows: initial denaturation at 95°C for 15 min, followed by 50 cycles of denaturation at 94°C for 15 s, annealing at 55°C for 15 s, and extension at 72°C for 15 s. The ␤-actin and miR103 gene was used as the reference. The PCR products were visualized by electrophoresis on 1.5% agarose gels with ethidium bromide staining to confirm the products.
Collection of small pulmonary arteries by LMD. LMD was performed on 14-m frozen sections that mounted on autoclaved polytarthalene stretched foil. Frozen sections were immersed in 70% ethanol for 3 min and then rapidly rinsed with RNase-free water. Sections were then rinsed in RNase-free water and were stained with Cresyl Violet to retrieve cells of the median wall of the small pulmonary arteries (50 -150 m) using the Leica AS LMD microdissection system (Leica Microsystems, Wetzlar, German). Total RNA was extracted from the collected small pulmonary arteries (ϳ50 vessels) using the RNeasy Micro kit (Qiagen), according to the manufacturer's protocol, and real-time RT-PCR of p21 was performed as described above.
Western blot analysis. Cytoplasmic and nuclear proteins from lungs and cells were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents, based on the manufacturer's protocol (Pierce, Rockford, IL), and the protein extracts were analyzed for protein content using a Bradford method. Each sample was quantified, and then 40 g of protein (cytoplasmic protein) or 20 g of protein (nuclear protein) were loaded into each lane of a 4 -12% Bis-Tris Nupage gel with MES-SDS running buffer, according to the manufacturer's protocol. The gel was transferred to a polyvinylidene difluoride membrane by electrophoresis, and the membrane was then probed with the primary and secondary antibodies. The ECL system was used for detection of the protein bands.
Statistical analysis. Results are expressed as means Ϯ SE. Statistical analysis was performed by ANOVA with Bonferroni correction for multiple comparisons. Comparisons were considered statistically significant at P Ͻ 0.05.
RESULTS

Analysis of body weight gain and polycythemia under chronic hypoxia.
Chronic hypoxia (10% oxygen) suppressed the body weight increase in WT and p53KO mice to an equal extent (Fig. 1A) . The hematocrit was significantly higher in the hypoxic vs. normoxic groups, but no difference was observed between WT and p53KO hypoxic mice (Fig. 1B) .
RV hypertrophy and RV pressure upon exposure to chronic hypoxia. RV and left ventricular function, as determined by echocardiography, appeared normal in all experimental conditions. Although the RV inner diameter in p53KO mice exposed to hypoxia did not show a significant increase (P ϭ 0.108) compared with normoxic p53KO mice ( Fig. 2A) , hypoxia significantly increased RV/LVϩS in both WT and p53KO mice compared with their respective normoxic controls. The increase in RV/LVϩS in the p53KO hypoxic mice was significantly greater than the increase seen in the WT hypoxic mice (Fig. 2B) . The RV systolic pressure was significantly increased by hypoxic exposure, and the increase was significantly greater in p53KO mice than in the WT mice (Fig. 2C) . However, there was no significant difference in RV diastolic pressure between WT and p53KO mice (Fig. 2D) . Although chronic hypoxia significantly increased the maximum rate of rise of RV pressure in both WT and p53KO mice compared with their respective normoxic controls, there was no significant difference in the heart rate nor in the maximum rate of rise of RV pressure between WT and p53KO mice (Fig. 2, E and F) .
The effect of chronic hypoxia on pulmonary vascular remodeling. The mean percent wall thickness of small pulmonary arteries significantly increased in both the WT and p53KO hypoxic groups compared with their respective normoxic controls. The increase of mean percent wall thickness in the p53KO hypoxic mice was significantly greater than that of the WT hypoxic mice (Fig. 3) . The number of proliferating vascular cells was significantly higher in hypoxia-exposed mice compared with normoxic controls, and the increase in the p53KO hypoxic mice was significantly greater than that of the normoxic mice (Fig. 4A) .
RT-PCR analysis of whole lung and small pulmonary arteries exposed to chronic hypoxia. In the whole lung analysis, p21 mRNA expression significantly increased on hypoxic exposure compared with normoxic controls; however, p21 mRNA expression was clearly reduced in both normoxic and hypoxic p53KO mice compared with WT mice. HIF-1␣ and p53 mRNA expression did not change significantly on hypoxic exposure in WT mice (Fig. 5A) . In the LMD analysis, p21 mRNA expression of small pulmonary arteries was significantly increased by hypoxic exposure compared with normoxic controls. Conversely, p21 mRNA expression was significantly suppressed in both normoxic and hypoxic p53KO mice compared with WT, consistent with the whole lung tissue analysis (Fig. 6) . The expression of miRNA34a was significantly in- ) . B: hematocrit of WT and p53KO mice exposed to normoxia or 8 wk of hypoxia. Chronic hypoxia induced polycythemia. There were no significant differences between WT and p53KO mice. Values are means Ϯ SE (n ϭ 6). *P Ͻ 0.05 vs. normoxic control.
creased on hypoxic exposure compared with normoxic control and significantly suppressed in p53KO mice. The increase of miR34a expression by hypoxic exposure was completely suppressed in p53KO mice (Fig. 5B) . The expression of VEGF, PDGF-A, PDGF-B, PDGF-D, and GLUT-1 was significantly increased on hypoxic exposure compared with normoxic control. There was a greater increase in expression of VEGF, PDGF-B, PDGF-D, and GLUT-1 in p53KO mice than that in the WT mice (Fig. 5C ).
Immunohistochemical and Western blot analysis of lungs exposed to chronic hypoxia. Immunohistochemical analysis showed that HIF-1␣ was expressed under hypoxic conditions mainly in the nucleus, whereas p53 appeared under hypoxic conditions both in the nucleus and cytosol only in the lungs from WT mice. The p21 protein was expressed under hypoxic conditions only in the lungs from WT mice, but not in those from the p53KO mice (Fig. 7A) . Western blot analysis of both cytosolic and nuclear fractions showed that HIF-1␣ protein expression both in the cytosol and the nuclear protein extracts was significantly increased by hypoxia, and the expression was also significantly increased in p53KO mice compared with the WT mice. The p21 protein expression was significantly increased by hypoxic exposure and significantly suppressed by p53 gene deficiency compared with normoxic WT mice, both in the cytosolic and nuclear fractions. The p53 protein expression was highly suppressed in p53KO mice and was significantly increased by hypoxia in WT mice compared with normoxic WT mice, both in the cytosolic and nuclear fraction Fig. 3 . Percent wall thickness of small pulmonary arteries exposed to chronic hypoxia. Representative photographs are shown of elastica-van Gieson (EVG) staining of small pulmonary arteries from WT and p53KO mice exposed to hypoxia for 8 wk. Percent wall thickness was expressed as the percentage of the medial wall thickness (the distance between the internal and external lamina) divided by the diameter of the vessel (the distance between the external lamina). Percent wall thickness was significantly increased by hypoxia in both WT and p53KO mice and increased to a larger extent in p53KO mice than in WT hypoxic mice (n ϭ 6). Bar graphs show data expressed as means Ϯ SE. *P Ͻ 0.05 vs. normoxic control. †P Ͻ 0.05 vs. WT mice. Fig. 2 . The effect of chronic hypoxia on right ventricular pressures and right ventricular hypertrophy. A: cardiac ultrasound showed that the right ventricular inner diameter (RVID) in p53KO mice exposed to hypoxia had a tendency to increase (P ϭ 0.108) compared with that in normoxic p53KO mice. B: chronic hypoxia significantly increased the ratio of right ventricular weight to left ventricular plus septal weight (RV/LVϩS) in both genotypes, but the increase in RV/LVϩS was larger in p53KO mice than in WT mice. Right ventricular systolic pressure (RVSP; C) and right ventricular diastolic pressure (RVDP; D) of WT and p53KO mice exposed to normoxia and hypoxia for 8 wk are shown. Chronic hypoxia resulted in higher RVSP, and p53KO mice had higher RVSP compared with WT mice. E: heart rate (HR) of WT and p53KO mice exposed to normoxia and hypoxia for 8 wk. There are no significant changes between these groups. F: the maximum rate of rise of ventricular pressure (dP/dt Max) of WT and p53KO mice exposed to normoxia and hypoxia for 8 wk. Chronic hypoxia increased the dP/dt Max in both genotypes. Values are means Ϯ SE (n ϭ 6). *P Ͻ 0.05 vs. normoxic control. †P Ͻ 0.05 vs. WT mice. (Fig. 7B) . PCNA protein expression in nuclear protein extracts from mouse lungs was significantly increased by hypoxic exposure and also increased in hypoxic p53KO mice compared with WT mice (Fig. 4B ).
DISCUSSION
The major findings of this study were that chronic hypoxic exposure in mice deficient in p53 resulted in more severe pulmonary hypertension, as evidenced by higher RV pressures, greater RV/LVϩS, and greater wall thickness of pulmonary vessels than in chronically hypoxic WT mice. Furthermore, we showed that p21 and p53 protein were both induced by hypoxia in WT mice, and that p53 gene deficiency was associated with decreased miR34a and p21 expression, which induce cell cycle arrest and apoptosis. In addition, increased HIF-1␣, VEGF, and PDGF-B and PDGF-D levels were confirmed in p53KO mice exposed to hypoxia. These data suggest that p53 is involved in the control of HIF-1␣-induced pulmonary vascular remodeling.
The p21 has been shown to regulate cell cycle progression through both p53-dependent and -independent pathways (7, 12, 29, 31) . In WT mice, hypoxia increased p21 expression and induced medial wall thickening of small pulmonary arteries, indicating that deletion of the p53 gene prevented the hypoxic induction of p21 expression and worsened the pulmonary arterial remodeling. These results indicate that, under hypoxic conditions, induction of the p53-p21 signaling pathway serves as a negative feedback to prevent excessive vascular cell proliferation and vascular remodeling. However, Gardner et al. (16) and Yu et al. (46) reported that hypoxic pulmonary arterial remodeling is unchanged in p21 knockout mice, and that p27, another CDK inhibitor, may play a mitigating role in hypoxiainduced pulmonary hypertension. A likely explanation for the discrepancy between this report and our results is the difference in duration of hypoxic exposure: only 2 wk in the studies of Yu et al. vs. 8 wk in our experiments. In our experiments, we did not find significant changes of RV systolic pressure and the RV/LVϩS ratio between p53KO mice and WT mice after a hypoxic exposure of 2 wk (Supplemental Fig. 3) , indicating perhaps that a relatively longer hypoxic exposure is required before differences of pulmonary vascular remodeling between p53KO mice and WT mice can be demonstrated.
Although, in mice, pulmonary vascular remodeling does not always relate to the degree of pulmonary hypertension, as shown by Daley et al. (11) , the pulmonary vascular remodeling was accompanied by pulmonary hypertension in our 8-wk hypoxia experiments.
Mutations in p53 and reduced expression of p27 are frequently observed concurrently in many human cancer cells, and reduced expression of p27 is a common feature in cancers harboring p53 mutations (13, 32, 33) . Wu and Schonthal (43) reported that, in serum-stimulated fibroblasts from p53KO mice, p21 could not be activated, but p27 protein could be induced without a decrease in cyclin A expression. Furthermore, our laboratory previously reported that p53 gene silencing was associated with decreased expression of p21 and increased proliferation and resulted in augmentation of p27 protein expression in cultured lung fibroblasts (30) . These findings implicate p27 as an important cell cycle regulator in cells that have a mutated p53 gene. However, further exami- Fig. 4 . Cell proliferation of small pulmonary arteries exposed to chronic hypoxia. A, top: representative photographs of immunohistochemical staining of proliferating cell nuclear antigen (PCNA) of small pulmonary arteries from WT and p53KO mice exposed to hypoxia for 8 wk.
Bottom: the bar graph shows that the number of PCNA-positive cells relative to the length of basal membrane in the medial wall of pulmonary vessels was increased in both WT and p53KO hypoxic groups and increased to a larger extent in p53KO hypoxic mice than in WT hypoxic mice. B, top: Western blot analysis of PCNA in whole lung of mice exposed to chronic hypoxia. PCNA expression was significantly increased after hypoxic exposure and increased in hypoxic p53KO mice. Bottom: the bar graph shows the ratio of PCNA protein expression relative to that of Lamin A/C. Values are means Ϯ SE (n ϭ 6). *P Ͻ 0.05 vs. normoxic control. †P Ͻ 0.05 vs. WT mice.
nation is required to clarify the role of p27 following loss of the p53 gene.
We found that deficiency of p53 leads to greater RV pressures and a greater degree of RV hypertrophy and vascular remodeling. However, it should be pointed out that the p53KO mice used in these studies are global knockout mice, and that the responses are not lung specific. We performed Western blot analysis of PCNA in the RVs to assess whether the lack of p53 gene expression would have primary effects on myocardial cell proliferation. Although there was no difference in RV PCNA levels between WT and the p53KO mice during normoxia, hypoxia increased the expression of PCNA in the RV in both the WT and p53KO mice compared with mice exposed to normoxia. p53KO mice exposed to chronic hypoxia have a greater degree of PCNA expression compared with the WT mice exposed to hypoxia (Supplemental Fig. 2 ). These data suggest that the mechanism of RV hypertrophy in chronically hypoxic mice is, to some degree, regulated by p53.
Our finding of decreased expression of miR34a in p53KO mice is in line with previous reports showing that miR34a is under the control of p53. In cancer cells, loss of miR34a has been linked to apoptosis resistance induced by p53 activating agents used in chemotherapy (21) , and miR34a has also been shown to induce apoptosis of cultured cells transiently transfected with this miR34a (8) . Our data showing increased expression of miR34a by hypoxia and suppression of this miRNA in p53KO mice suggest that miR34a was regulated by hypoxia-induced accumulation of p53. Thus miR34a may also be involved in the signaling leading to hypoxic vascular remodeling in the lung.
Increased levels of growth factors induced by accumulation of HIF-1␣ have been thought to regulate PASMC proliferation under hypoxic conditions, since partial HIF-1␣ deficiency decreases muscularization of pulmonary arterioles in animals exposed to chronic hypoxia (44) . Although HIF-1␣ regulates various transcriptional genes for angiogenic factors, severe hypoxia and iron depletion induce cell growth arrest. In the present study, we found that p53 protein expression increased Fig. 6 . p21 mRNA analysis of small pulmonary arteries using laser capture microdissection (LMD). LMD was performed on 14-m frozen sections that were stained with cresyl violet to retrieve cells of the median wall of the small pulmonary. Shown are representative photographs from the captured small pulmonary arteries (diameter 50 -150 m) (A), lumens of small arteries were removed (B), and the medial walls of pulmonary arteries were captured and collected (C). p21 mRNA expression of small pulmonary arteries was increased by hypoxia and suppressed by p53 gene deficiency. The bar graphs show the ratios of p21 mRNA relative to control. ␤-Actin was used as a reference. Values are means Ϯ SE (n ϭ 6). *P Ͻ 0.05 vs. 21% oxygen control.
†P Ͻ 0.05 vs. WT. Fig. 5 . RT-PCR analysis of mRNA and microRNA (miRNA) of whole lungs exposed to chronic hypoxia. A: hypoxia-inducible factor (HIF)-1␣, p21, and p53 mRNA expression of whole lungs from WT and p53KO mice exposed to normoxia or hypoxia for 8 wk. p21 mRNA expression was significantly increased by hypoxic exposure in WT mice. In p53KO mice, the expression of p21 mRMA was significantly suppressed compared with that in WT mice and did not change significantly with exposure to hypoxia. The bar graphs show the ratios of HIF-1␣, p53, and p21 mRNA relative to the amount of control. ␤-Actin was used as a reference. HIF-1␣ and p53 mRNA expression did not change by hypoxic exposure. B: miR34a expression of whole lungs from WT and p53KO mice exposed to normoxia and hypoxia for 8 wk. after hypoxic exposure in vivo, and that the increased p53 protein accumulation induced p21 mRNA and protein expression. This is consistent with previous studies in hypoxic cell cultures and with results from studies in which anoxia was chemically induced (3, 15) . The p53 protein expression ordinarily relies on posttranscriptional events, given that p53 protein is a very short-lived protein, owing to fast proteasomal degradation, and stabilization of the protein in response to a variety of stresses, including hypoxic stress, has been found to evoke a rapid increase in p53 levels (19) . We also demonstrated that p53 gene deletion resulted in increased expression of HIF-1␣ protein expression in mouse lungs. Sano et al. (39) and Kim et al. (25) reported that increased p53 expression was involved in the downregulation of HIF-1␣ protein expression in the heart. Prolonged or severe hypoxia has been reported to induce p53, which binds to HIF-1␣, promoting its degradation and inhibiting its transactivation properties (5, 37) . From this point of view, we propose that the deletion of p53 caused an increased expression of HIF-1␣ and its signal transduction toward angiogenesis. The increased expression of VEGF and GLUT-1 mRNA associated with deletion of the p53 gene supports the hypothesis that HIF-1␣-dependent transactivation is enhanced in association with the increased HIF-1␣ protein expression in the lungs of p53KO mice.
In conclusion, we have demonstrated that p53 plays a critical role as a modulator of hypoxia-induced small pulmonary arterial remodeling. Decreased expression of p21 and increased expression of HIF-1␣ via suppression of p53 protein may mitigate hypoxic pulmonary arterial remodeling and pulmonary arterial smooth muscle proliferation. We believe that a Fig. 7 . Immunohistochemical and Western blot analysis of whole lung of mice exposed to chronic hypoxia. A: representative photographs of immunohistochemical staining of HIF-1␣, p53, and p21 of small pulmonary arteries from WT and p53KO mice exposed to hypoxia for 8 wk. HIF-1␣ was expressed under hypoxic conditions mainly in the nucleus, whereas p53 appeared under hypoxic conditions in both the nucleus and cytosol only in the lungs from WT mice. The p21 protein was expressed under hypoxic conditions only in the lungs from WT mice, but not in those from the p53KO mice. B: representative photographs of HIF-1␣, p53, p21, and Lamin A/C expression from lung nuclear protein and cytosolic protein extracts. HIF-1␣ expression was significantly increased after hypoxic exposure and increased to a larger extent in hypoxic p53KO mice in both the nuclear and cytosolic fraction. The p53 protein expression significantly increased after hypoxic exposure in WT mice and was highly suppressed in p53KO mice. The p21 protein expression was significantly increased after hypoxic exposure in WT mice and suppressed in p53KO mice. The left bar graph shows the ratios of protein expression relative to that of Lamin A/C from nuclear fraction, and the right bar graph shows the ratios of protein expression relative to that of ␤-actin from cytosolic fraction. Open bar, WT-N; solid bar, KO-N; dark shaded bar, WT-Hx; light shaded bar, p53KO-Hx. Values are means Ϯ SE (n ϭ 6). *P Ͻ 0.05 vs. normoxic control. †P Ͻ 0.05 vs. WT.
better understanding of the genetic and cellular mechanisms of hypoxic pulmonary remodeling will lead to improved modes of therapy for hypoxia-associated changes in lung tissue structure and aid in the remodeling of pulmonary hypertension.
